Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Inclusion Criteria:
- Postmenopausal patients, defined as one or more of the following criteria:
Documented history of bilateral oophorectomy, Aged 60 years or more,
Aged 45-59 years and satisfying one or more of the following criteria:
Amenorrhea for at least 12 months and intact uterus Amenorrhea for less than 12 months and
follicle stimulating hormone (FSH) concentrations within postmenopausal range including:
patients who have had a hysterectomy and patients who have received hormone replacement
therapy in the past.
- Clinically palpable or non-palpable T1c or greater, ER positive invasive breast
cancer diagnosed by outside core biopsy.
- Outside diagnosis of invasive breast cancer confirmed at MSKCC
- Palpable or non-palpable breast mass > 1cm highly suspicious for invasive breast
cancer based on mammographic, ultrasound and/or physical examination findings and
amenable to diagnostic core biopsy.
- Core biopsy diagnosis of ER positive invasive breast cancer performed at MSKCC
- Breast conserving surgery or mastectomy scheduled at MSKCC.
- Informed consent obtained.
Exclusion Criteria:
- Co-morbid conditions which would preclude use of aromatase inhibitors such as:
previous hypersensitivity, severe hepatic insufficiency (SGOT or SGPT three times the
upper limit of normal), severe renal insufficiency (creatinine clearance <10ml/min).
Prior radiation therapy to chest wall / breast.
- Neoadjuvant chemotherapy
- Hormone replacement therapy, tamoxifen or raloxifene treatment within past 3 months
- ER negative breast cancer
- History of active malignancy within the previous 5 years (except for nonmelanoma skin
cancer and breast cancer)